Abstract:Sialic acid is the receptor determinant for the human parainfluenza virus type 3 (HPF3) hemagglutinin-neuraminidase (HN) glycoprotein, the molecule responsible for binding of the virus to cell surfaces. In order for the fusion protein (F) of HPF3 to promote membrane fusion, HN must interact with its receptor. In addition to its role in receptor binding and fusion promotion, the HPF3 HN molecule contains receptor-destroying (sialidase) activity. The putative active sites are in the extracellular domain of this type II integral membrane protein. However, HN is not available in crystalline form; the exact locations of these sites, and the structural requirements for binding to the cellular receptor, which has not yet been isolated, are unknown. Nor have small molecular synthetic inhibitors of attachment or fusion that would provide insight into these processes been identified. The strategy in the present study was to develop an assay system that would provide a measure of a specific step in the viral cycle-functional interaction between viral glycoproteins and the cell during attachment and fusion-and serve to screen a variety of substances for inhibitory potential. The assay is based on our previous finding that CV-1 cells persistently infected (p.i.) with HPF3 do not fuse with one another but that the addition of uninfected CV-1 cells, supplying the critical sialic acid containing receptor molecules that bind HN, results in rapid fusion. In the present assay two HeLa cell types were used: we persistently infected HeLa-LTR-betagal cells, assessed their fusion with uninfected HeLa-tat cells, and then quantitated the beta-galactosidase (betagal) produced as a result of this fusion. The analog alpha-2-S-methyl-5-N-thioacetylneuraminic acid (alpha-Neu5thioAc2SMe) interfered with fusion, decreasing betagal production by 84% at 50 mM and by 24% at 25 mM. In beginning to extend our studies to different types of molecules, we tested an unsaturated derivative of sialic acid, 2,3-dehydro-2-deoxy-n-acetyl neuraminic acid (DANA), which is known to inhibit influenza neuraminidase by virtue of being a transition-state analog. We found that 10 mM DANA inhibited neuraminidase activity in HPF3 viral preparations. More significantly, this compound was active in our assay of HN-receptor interaction; 10 mM DANA completely blocked fusion and betagal production, and hemadsorption inhibition by DANA suggested that DANA blocks attachment. In plaque reduction assays performed with the compounds, the active analog alpha-Neu5thioAc2SMe reduced plaque formation by 50% at a 50 mM concentration; DANA caused a 90% inhibition in the plaque reduction assay at a concentration of 25 mM. Our results indicate that specific sialic acid analogs that mimic the cellular receptor determinant of HPF3 can block virus cell interaction and that an unsaturated n-acetyl-neuraminic acid derivative with affinity to the HN site responsible for neuraminidase activity also interferes with HN-receptor binding. Strategies suggested by these findings are now being pursued to obtain information regarding the relative locations of the active sites of HN and to further elucidate the relationship between the receptor-binding and receptor-destroying activities of HN during the viral life cycle. The quantitative assay that we describe is of immediate applicability to large-scale screening for potential inhibitors of HPF3 infection in vivo.

Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating cell fusion-dependent reporter gene activation

A Virus Genetic System to Analyze the Fusogenicity of Human Cytomegalovirus Glycoprotein B Variants.

A Sensitive Hiv-1 Envelope Induced Fusion Assay Identifies Fusion Enhancement of Thrombin

A fluorogenic pseudo-infection assay to probe transfer and distribution of influenza viral contents to target vesicles

A Fluorogenic Pseudoinfection Assay to Probe Transfer and Distribution of Influenza Viral Contents to Target Vesicles

Expression of the Newcastle Disease Virus Fusion Glycoprotein in Vero Cells Using Attenuated Salmonella Typhimurium As Transgenic Carrier

Short Communication: in VitroSynergy Between Peptides or Neutralizing Antibodies Targeting the N- and C-Terminal Heptad Repeats of HIV Type 1 Gp41

The Molecular Mechanism of Enveloped Virus-Cell Membrane Fusion

A Non-Infectious Assay for Detecting HIV Env-induced Cell-Cell Fusion

Analysis of gene mutation in the interaction domain of head and stalk of Newcastle disease virus hemagglutinin-neuraminidase glycoprotein

Prokaryotic expression of structural domains of the Newcastle disease virus fusion protein and analyses of their antigenic epitopes

Expression of the Extracellular Domain of the Human Immunodeficiency Virus Type 1 Envelope Protein and Its Fusion with Β-Galactosidase in Saccharomyces Cerevisiae

Expression and Immunogenicity of Two Recombinant Fusion Proteins Comprising Foot-and-Mouth Disease Virus Structural Protein VP1 and DC-SIGN-Binding Glycoproteins

Mechanism of membrane fusion induced by vesicular stomatitis virus G protein

The membrane fusion step of vaccinia virus entry is cooperatively mediated by multiple viral proteins and host cell components

The vaccinia chondroitin sulfate binding protein drives host membrane curvature to facilitate fusion

Mutational Analysis of Virus Specific Amino Acids in the Fusion Active Domain of Paramyxovirus Fusion Protein

Preliminary Identification of an Active Domain on Fusion Protein of Paramyxoviruses

[A Non-Infectious and Quantitative Cell-Based Bioassay for Screening HIV Entry Inhibitors Targeting HIV Envelope Proteins].

The use of a quantitative fusion assay to evaluate HN-receptor interaction for human parainfluenza virus type 3

An exploration of conditions proposed to trigger the Ebola virus glycoprotein for fusion